Changes in Hong Kong stocks | Collumbotai Bio-B (06990) rose more than 6% ITGB6 ADC SKB105 new drug clinical trial application approved

The Zhitong Finance App learned that Columbite Biotech (06990) rose by more than 6%. As of press release, it had risen 5.89% to HK$427.2, with a turnover of HK$129 million.

According to the news, on January 4, Columbotai Bio-B announced that the new drug clinical trial (IND) application for the targeted integrin beta-6 (ITGB6) antibody conjugate drug (ADC) SKB105 (also known as CR-003) independently developed by the company has been approved by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for the treatment of advanced solid tumors.

In December 2025, the company and Crescent Biopharma, Inc. reached a strategic cooperation on SKB105/CR-003 and SKB118 (programmed cell death protein-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody, also known as CR-001), in which the company awarded Crescent to research, develop, produce and commercialize SKB105/CR-003 in markets outside the US, Europe and all other Greater China regions (including mainland China, Hong Kong, Macau and Taiwan) Exclusive rights. Crescent grants the company exclusive rights to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China.

The company plans to submit an IND application for SKB118/CR-001 to the Drug Evaluation Center of the China National Drug Administration in the near future.